Molecular targeting therapy for pancreatic cancer: Current knowledge and perspectives from bench to bedside

Toru Furukawa

doi:10.1007/s00535-008-2226-1

Molecular targeting therapy for pancreatic cancer: Current knowledge and perspectives from bench to bedside

Toru Furukawa

MED - Medical Sciences

Research output: Contribution to journal › Review article › peer-review

44 Citations (Scopus)

Abstract

Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.

Original language	English
Pages (from-to)	905-911
Number of pages	7
Journal	Journal of Gastroenterology
Volume	43
Issue number	12
DOIs	https://doi.org/10.1007/s00535-008-2226-1
Publication status	Published - 2008

Keywords

Hedgehog
Molecular targeting
Pancreatic cancer
PI3K-AKT
RAS-MAPK

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00535-008-2226-1

Cite this

@article{3a2735c64f1d4055873efd9f9325903c,

title = "Molecular targeting therapy for pancreatic cancer: Current knowledge and perspectives from bench to bedside",

abstract = "Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.",

keywords = "Hedgehog, Molecular targeting, Pancreatic cancer, PI3K-AKT, RAS-MAPK",

author = "Toru Furukawa",

year = "2008",

doi = "10.1007/s00535-008-2226-1",

language = "English",

volume = "43",

pages = "905--911",

journal = "Journal of Gastroenterology",

issn = "0944-1174",

publisher = "Springer Japan",

number = "12",

}

TY - JOUR

T1 - Molecular targeting therapy for pancreatic cancer

T2 - Current knowledge and perspectives from bench to bedside

AU - Furukawa, Toru

PY - 2008

Y1 - 2008

N2 - Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.

AB - Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.

KW - Hedgehog

KW - Molecular targeting

KW - Pancreatic cancer

KW - PI3K-AKT

KW - RAS-MAPK

UR - http://www.scopus.com/inward/record.url?scp=58149203295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149203295&partnerID=8YFLogxK

U2 - 10.1007/s00535-008-2226-1

DO - 10.1007/s00535-008-2226-1

M3 - Review article

C2 - 19107333

AN - SCOPUS:58149203295

SN - 0944-1174

VL - 43

SP - 905

EP - 911

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

IS - 12

ER -

Molecular targeting therapy for pancreatic cancer: Current knowledge and perspectives from bench to bedside

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this